Nuclear Medicine Program progress report for quarter ending June 30, 1996

The four stereoisomers of 1-azabicyclo[2.2.2]oct-3-yl {alpha}-(1fluoropent-5-yl)-{alpha}-hydroxy-{alpha}-phenylacetate (FQNPe, 4) have been resolved and were evaluated as potential candidates for PET imaging agents. Labeling with fluorine-18 involved a two-step synthesis via fluoride displacement of a mesylate intermediate at the ethyl ester stage followed by transesterification with (R)-quinuclidinol. In vitro data utilizing cloned human receptor subtypes demonstrated that while the (+,+)-isomer did not have significant receptor binding, the other stereoisomers of FNPe bound with high affinity to the various mA ChR subtypes tested (K{sub i}, nm: m1, ({minus},{minus}), 0.33; ({minus},+), 1.4; (+,{minus}), 3.8; m2, ({minus},{minus}), 0.1; ({minus},+), 4.2; +,{minus}), < 75% binding; m3, ({minus},{minus}), 0.34; ({minus},+), 3.1; (+;{minus}), 7.6. [{sup 18}F]-({minus},{minus})- and [{sup 18}F]-({minus},+)-FQNPe (4) were prepared in decay corrected radiochemical yields of 14% ([{sup 18}F]-({minus},{minus})-4) and 8% ([{sup 18}F]-({minus},+)-4). In vivo biodistribution studies were conducted in female rats with [18F]-({minus},{minus})- and (+,{minus})-FQNPe (4). [{sup 18}F]({minus},{minus})-4 demonstrated high uptake in mA ChR regions of the brain up to 3 hours post injection and low accumulation of radioactivity in the bone indicated good in vivo stability.